United Therapeutics Corporation
NASDAQ:UTHRBiotechnology
-$18.01 today
- Market cap
- $24.59B
- Beta
- 0.57
- P/E (TTM)
- 18.0
- EPS (TTM)
- $29.60
Volume 0.42M
Average 0.52M
UTHR Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
United Therapeutics CorporationNASDAQ: UTHR
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development growth accelerates
Q2 FY2026 research & development of $146.3M rose 9.2% year over year, ahead of the +6.0% change in trailing-twelve-month research & development. Sequentially, it rose 5.9% from the prior quarter. Over 3 fiscal years it compounded at +19.4% a year.
Context
- Research & development amounted to 17.3% of revenue in FY2025, up 0.6 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +9.2% holds above the trailing-twelve-month pace of +6.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 550M USD
- Year-over-year change
- +14.3%
- 4-year CAGR
- +0.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 550M | +14.3% |
| FY2024 | 2024-12-31 | 481M | +17.9% |
| FY2023 | 2023-12-31 | 408M | +26.4% |
| FY2022 | 2022-12-31 | 322.9M | -40.2% |
| FY2021 | 2021-12-31 | 540.1M | — |
Research & Development vs competitors
How UTHR compares with its peers on the latest reported figures
- UTHR's LTM Jun 2026 research & development of $551.5M is the 2nd highest of the 5 companies compared; the peer median is $150.65M.
- Its year-over-year change of +6.0% is the lowest of 5, against a peer median of +25.5%.
- Research & development amounts to 17.5% of revenue for UTHR, versus a peer median of 37.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $860.85M | +30.4% | +24.7% | 75.7% | |
| LTM Jun 2026 | $551.5M | +6.0% | +19.4% | 17.5% | |
| LTM Sep 2026 | $245.55M | +16.8% | -3.2% | 37.7% | |
| LTM Jun 2026 | $55.75M | +34.8% | +26.4% | 12.4% | |
| LTM Mar 2026 | $30.12M | +20.6% | +35.3% | — | |
| Peer median (excluding UTHR) | $150.65M | +25.5% | +25.6% | 37.7% | |
Competitors are the stored peer set for UTHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.69B | 1.94B | 2.33B | 2.88B | 3.18B |
| Cost of Revenue | 122.5M | 146.7M | 257.5M | 309.7M | 384.4M |
| Gross Profit | 1.56B | 1.79B | 2.07B | 2.57B | 2.8B |
| Gross Margin | 92.7% | 92.4% | 88.9% | 89.2% | 87.9% |
| Research & Development | 540.1M | 322.9M | 408M | 481M | 550M |
| Selling, General & Admin | 467M | 487M | 477.1M | 638.6M | 731.1M |
| Operating Expenses | 1.01B | 809.9M | 885.1M | 1.19B | 1.28B |
| Depreciation & Amortization | 49.9M | 51.3M | 53.2M | 72.5M | 85.6M |
| EBITDA | 736.8M | 1.04B | 1.39B | 1.65B | 1.82B |
| EBITDA Margin | 43.7% | 53.7% | 59.6% | 57.5% | 57.2% |
| Operating Income | 555.9M | 979.7M | 1.18B | 1.38B | 1.52B |
| Operating Margin | 33.0% | 50.6% | 50.9% | 47.9% | 47.7% |
| Interest Income | 16.7M | 45.2M | 162.7M | 199.1M | 192M |
| Interest Expense | 18.6M | 32.4M | 59.3M | 42.9M | 19.5M |
| Other Income / Expenses | 38M | (29.1M) | 89.4M | 162M | 196.7M |
| Income Before Tax | 593.9M | 950.6M | 1.27B | 1.54B | 1.71B |
| Pre-Tax Margin | 35.2% | 49.1% | 54.7% | 53.5% | 53.9% |
| Income Tax Expense | 118.1M | 223.3M | 289.5M | 343.9M | 379.2M |
| Net Income | 475.8M | 727.3M | 984.8M | 1.2B | 1.33B |
| Net Margin | 28.2% | 37.6% | 42.3% | 41.5% | 41.9% |
| EPS (Basic) | 10.60 | 15.98 | 21.04 | 26.44 | 30.13 |
| EPS (Diluted) | 10.06 | 15.00 | 19.81 | 24.64 | 27.86 |
| Weighted Avg Shares | 44.9M | 45.5M | 46.8M | 45.2M | 44.3M |
| Weighted Avg Shares (Diluted) | 47.3M | 48.5M | 49.7M | 48.5M | 47.9M |
United Therapeutics Corporation
NASDAQ:UTHR
Intrinsic Alpha fair value
Locked
Current Price
$577.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.